ELV Shares Dip on Medicaid Cost Surge Weak Outlook

Introduction

Elevance Health (NYSE: ELV) experienced renewed downward pressure on its stock in the final days of February 2026 as investors digested continued cost inflation in Medicaid and Affordable Care Act (ACA) business and the company’s cautious 2026 guidance. Although ELV’s Carelon health services unit remains a bright spot, elevated benefit expense ratios and a profit outlook below Wall Street expectations have shaped short-term sentiment.

What moved ELV this week

Over the trading week spanning Feb. 23–26, ELV posted several swings that reflected investor unease rather than any single new corporate announcement:

• Feb. 23: Shares dropped roughly 2.1% to about $335.87 amid a broad pullback.
• Feb. 24: The stock fell another ~2.6% to near $327.14.
• Feb. 25: A modest rebound lifted ELV about 1.0% to $330.51.
• Feb. 26: ELV declined again by roughly 2.3% to $323.05 and showed heavier-than-normal volume.

Across those sessions ELV underperformed several peers on select days, reflecting investor sensitivity to guidance and persistent medical-cost pressures across core insurance lines.

Driver: Elevated medical costs in public plans

Investors are focused on the carrier’s exposure to Medicaid and ACA book-of-business, where utilization and unit-cost trends have remained elevated. In its late-January disclosures, Elevance flagged that ongoing medical trends would weigh on margins and lead to a modest revenue decline and profit results below consensus for 2026. That guidance, rather than a fresh operational surprise this week, is the principal proximate cause of the recent share volatility.

Underlying fundamentals: Q4 2025 and 2026 guidance

Key financial signals that continue to influence market perception:

• Q4 2025 net income was reported at $547 million, but margin compression was clear as benefit expense jumped.
• Elevance’s benefit expense ratio spiked to approximately 93.5% in Q4, with an annual benefit expense ratio near 90%—a level that constrains underwriting profit and free cash flow.
• January 28 guidance for 2026 projected slightly lower revenue and profit below analyst expectations, driven primarily by sustained cost pressure in Medicaid and ACA products.

Carelon: a partial offset

The company’s Carelon health services segment continues to deliver strong revenue growth and margins relative to core Health Benefits lines. Management has highlighted Carelon’s role as a strategic diversification away from traditional underwriting, and investors view it as a structural positive for long-term earnings mix—even if it’s not large enough yet to fully neutralize rising medical costs in the near term.

What this means for investors

Short-term: The stock’s weakness reflects credible, quantifiable headwinds—rising benefit expense and conservative 2026 guidance—rather than unfounded speculation. For traders, those conditions raise the bar for positive earnings surprises or tangible signs of trend improvement in Medicaid/ACA utilization.

Intermediate-to-long-term: Elevance’s fundamentals are mixed. On one hand, elevated medical costs compress underwriting margins; on the other, Carelon’s growth and the company’s scale in Medicare Advantage provide meaningful competitive advantages. The near-term stock trajectory will depend on whether benefit expense ratios moderate and whether management provides clearer signs of cost control or margin recovery.

Risk factors to monitor

• Medicaid and ACA utilization trends and pricing resets.
• Quarterly benefit expense ratio disclosures and any trajectory changes versus Q4’s ~93.5% print.
• Guidance revisions or incremental commentary from management about pricing, provider negotiations, or care-management gains at Carelon.

Conclusion

ELV’s price action this week reflects a market that is re-pricing risk around sustained medical-cost inflation in public plan portfolios and a 2026 outlook that leaves earnings below consensus. While Carelon offers diversification and growth, investors will need to see tangible improvement in benefit expense trends or clearer margin-restoration steps before sentiment stabilizes. The coming quarterly updates and any incremental commentary on Medicaid/ACA cost trends will be the most important catalysts for the stock.